JP6821908B2 - 哺乳動物種における誘導組織再生のための組成物および方法 - Google Patents
哺乳動物種における誘導組織再生のための組成物および方法 Download PDFInfo
- Publication number
- JP6821908B2 JP6821908B2 JP2019091651A JP2019091651A JP6821908B2 JP 6821908 B2 JP6821908 B2 JP 6821908B2 JP 2019091651 A JP2019091651 A JP 2019091651A JP 2019091651 A JP2019091651 A JP 2019091651A JP 6821908 B2 JP6821908 B2 JP 6821908B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- gene
- progenitor cells
- cox7a1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000017423 tissue regeneration Effects 0.000 title description 231
- 238000000034 method Methods 0.000 title description 144
- 239000000203 mixture Substances 0.000 title description 78
- 210000004027 cell Anatomy 0.000 claims description 424
- 108090000623 proteins and genes Proteins 0.000 claims description 218
- 150000001875 compounds Chemical class 0.000 claims description 127
- 230000014509 gene expression Effects 0.000 claims description 117
- -1 LOC205251 Proteins 0.000 claims description 77
- 241000282414 Homo sapiens Species 0.000 claims description 74
- 150000007523 nucleic acids Chemical class 0.000 claims description 71
- 102000039446 nucleic acids Human genes 0.000 claims description 70
- 108020004707 nucleic acids Proteins 0.000 claims description 70
- 239000003795 chemical substances by application Substances 0.000 claims description 63
- 210000000130 stem cell Anatomy 0.000 claims description 62
- 108020004459 Small interfering RNA Proteins 0.000 claims description 45
- 101000964390 Homo sapiens Zinc finger protein 280D Proteins 0.000 claims description 43
- 102100040319 Zinc finger protein 280D Human genes 0.000 claims description 43
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 37
- 239000013598 vector Substances 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 101001019605 Homo sapiens Isoamyl acetate-hydrolyzing esterase 1 homolog Proteins 0.000 claims description 29
- 102100035008 Isoamyl acetate-hydrolyzing esterase 1 homolog Human genes 0.000 claims description 29
- 101000844252 Homo sapiens TYMS opposite strand protein Proteins 0.000 claims description 26
- 102100032009 TYMS opposite strand protein Human genes 0.000 claims description 26
- 230000009368 gene silencing by RNA Effects 0.000 claims description 26
- 230000002401 inhibitory effect Effects 0.000 claims description 26
- 239000002243 precursor Substances 0.000 claims description 26
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims description 24
- 102100040999 Catechol O-methyltransferase Human genes 0.000 claims description 23
- 102100023965 Dynein light chain Tctex-type 3 Human genes 0.000 claims description 23
- 102100038795 E3 ubiquitin-protein ligase TRIM4 Human genes 0.000 claims description 23
- 101000904012 Homo sapiens Dynein light chain Tctex-type 3 Proteins 0.000 claims description 23
- 101000664604 Homo sapiens E3 ubiquitin-protein ligase TRIM4 Proteins 0.000 claims description 23
- 101000658628 Homo sapiens Testis-specific Y-encoded-like protein 5 Proteins 0.000 claims description 23
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 claims description 23
- 102000005881 S100 Calcium Binding Protein A6 Human genes 0.000 claims description 23
- 108010005260 S100 Calcium Binding Protein A6 Proteins 0.000 claims description 23
- 101710084636 Serine hydroxymethyltransferase Proteins 0.000 claims description 23
- 102100021225 Serine hydroxymethyltransferase, cytosolic Human genes 0.000 claims description 23
- 101710099809 Serine hydroxymethyltransferase, cytosolic Proteins 0.000 claims description 23
- 101710087362 Serine hydroxymethyltransferase, mitochondrial Proteins 0.000 claims description 23
- 102100034914 Testis-specific Y-encoded-like protein 5 Human genes 0.000 claims description 23
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 claims description 23
- 102100024088 40S ribosomal protein S7 Human genes 0.000 claims description 22
- 102100028704 Acetyl-CoA acetyltransferase, cytosolic Human genes 0.000 claims description 22
- 101000690200 Homo sapiens 40S ribosomal protein S7 Proteins 0.000 claims description 22
- 101000837584 Homo sapiens Acetyl-CoA acetyltransferase, cytosolic Proteins 0.000 claims description 22
- 101000642613 Homo sapiens Sterol O-acyltransferase 2 Proteins 0.000 claims description 22
- 230000002708 enhancing effect Effects 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 208000027418 Wounds and injury Diseases 0.000 claims description 21
- 239000002679 microRNA Substances 0.000 claims description 21
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 19
- 102100039249 Elongation of very long chain fatty acids protein 6 Human genes 0.000 claims description 18
- 108050007786 Elongation of very long chain fatty acids protein 6 Proteins 0.000 claims description 18
- 101001076680 Homo sapiens Insulin-induced gene 1 protein Proteins 0.000 claims description 18
- 102100025887 Insulin-induced gene 1 protein Human genes 0.000 claims description 18
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 18
- 108091070501 miRNA Proteins 0.000 claims description 15
- 102100035111 Farnesyl pyrophosphate synthase Human genes 0.000 claims description 14
- 101001023007 Homo sapiens Farnesyl pyrophosphate synthase Proteins 0.000 claims description 14
- 108010017842 Telomerase Proteins 0.000 claims description 14
- 239000000017 hydrogel Substances 0.000 claims description 14
- 239000004055 small Interfering RNA Substances 0.000 claims description 14
- 230000003197 catalytic effect Effects 0.000 claims description 13
- 230000029663 wound healing Effects 0.000 claims description 13
- 206010052428 Wound Diseases 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 10
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 8
- 229920002674 hyaluronan Polymers 0.000 claims description 8
- 229960003160 hyaluronic acid Drugs 0.000 claims description 8
- 238000011065 in-situ storage Methods 0.000 claims description 8
- 239000013603 viral vector Substances 0.000 claims description 8
- 210000003780 hair follicle Anatomy 0.000 claims description 7
- 210000004072 lung Anatomy 0.000 claims description 7
- 210000003205 muscle Anatomy 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 7
- 230000008685 targeting Effects 0.000 claims description 7
- 102100036732 Actin, aortic smooth muscle Human genes 0.000 claims description 6
- 101000929319 Homo sapiens Actin, aortic smooth muscle Proteins 0.000 claims description 6
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 claims description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 210000002510 keratinocyte Anatomy 0.000 claims description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 4
- 230000001537 neural effect Effects 0.000 claims description 4
- 210000000963 osteoblast Anatomy 0.000 claims description 4
- 239000002924 silencing RNA Substances 0.000 claims description 4
- 101150116687 COX7A1 gene Proteins 0.000 claims description 3
- 108090000994 Catalytic RNA Proteins 0.000 claims description 3
- 102000053642 Catalytic RNA Human genes 0.000 claims description 3
- 108010022452 Collagen Type I Proteins 0.000 claims description 3
- 102000012422 Collagen Type I Human genes 0.000 claims description 3
- 230000003511 endothelial effect Effects 0.000 claims description 3
- 210000003494 hepatocyte Anatomy 0.000 claims description 3
- 210000004216 mammary stem cell Anatomy 0.000 claims description 3
- 210000003098 myoblast Anatomy 0.000 claims description 3
- 210000005155 neural progenitor cell Anatomy 0.000 claims description 3
- 108091092562 ribozyme Proteins 0.000 claims description 3
- 102100025629 Cytochrome c oxidase subunit 7A1, mitochondrial Human genes 0.000 claims 10
- 101000856748 Homo sapiens Cytochrome c oxidase subunit 7A1, mitochondrial Proteins 0.000 claims 10
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 4
- 108010062431 Monoamine oxidase Proteins 0.000 claims 4
- 108091030071 RNAI Proteins 0.000 claims 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 2
- 108091005461 Nucleic proteins Proteins 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 210000003321 cartilage cell Anatomy 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 description 118
- 239000003112 inhibitor Substances 0.000 description 109
- 108090000765 processed proteins & peptides Proteins 0.000 description 109
- 102000004196 processed proteins & peptides Human genes 0.000 description 102
- 229920001184 polypeptide Polymers 0.000 description 100
- 239000012190 activator Substances 0.000 description 62
- 238000011069 regeneration method Methods 0.000 description 61
- 230000008929 regeneration Effects 0.000 description 60
- 235000001014 amino acid Nutrition 0.000 description 51
- 229940024606 amino acid Drugs 0.000 description 49
- 150000001413 amino acids Chemical class 0.000 description 49
- 210000000056 organ Anatomy 0.000 description 46
- 238000003556 assay Methods 0.000 description 41
- 230000000694 effects Effects 0.000 description 39
- 238000000338 in vitro Methods 0.000 description 39
- 239000000047 product Substances 0.000 description 39
- 210000001082 somatic cell Anatomy 0.000 description 39
- 238000012360 testing method Methods 0.000 description 33
- 108020004999 messenger RNA Proteins 0.000 description 28
- 210000000988 bone and bone Anatomy 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 26
- 230000001605 fetal effect Effects 0.000 description 25
- 238000011161 development Methods 0.000 description 24
- 230000018109 developmental process Effects 0.000 description 24
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 22
- 239000000463 material Substances 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 21
- 238000001514 detection method Methods 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 20
- 210000002308 embryonic cell Anatomy 0.000 description 19
- 230000033667 organ regeneration Effects 0.000 description 19
- 102100028661 Amine oxidase [flavin-containing] A Human genes 0.000 description 18
- 101000694718 Homo sapiens Amine oxidase [flavin-containing] A Proteins 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 150000003384 small molecules Chemical class 0.000 description 18
- 241000894007 species Species 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 102100029279 Homeobox protein SIX1 Human genes 0.000 description 17
- 101000634171 Homo sapiens Homeobox protein SIX1 Proteins 0.000 description 17
- 230000006378 damage Effects 0.000 description 17
- 210000001654 germ layer Anatomy 0.000 description 17
- 230000000451 tissue damage Effects 0.000 description 17
- 231100000827 tissue damage Toxicity 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 102100031890 Aminopeptidase NAALADL1 Human genes 0.000 description 15
- 101001128146 Homo sapiens Aminopeptidase NAALADL1 Proteins 0.000 description 15
- 210000000601 blood cell Anatomy 0.000 description 15
- 238000010208 microarray analysis Methods 0.000 description 15
- 239000002777 nucleoside Substances 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 101000864690 Homo sapiens Homeobox protein DLX-1 Proteins 0.000 description 14
- 101001099887 Homo sapiens Rab-3A-interacting protein Proteins 0.000 description 14
- 101100519066 Pan troglodytes PCDHB17 gene Proteins 0.000 description 14
- 101100519069 Pan troglodytes PCDHB18 gene Proteins 0.000 description 14
- 102100038475 Rab-3A-interacting protein Human genes 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 102100024387 AF4/FMR2 family member 3 Human genes 0.000 description 13
- 102100030087 Homeobox protein DLX-1 Human genes 0.000 description 13
- 101000833166 Homo sapiens AF4/FMR2 family member 3 Proteins 0.000 description 13
- 101000986765 Homo sapiens Oxytocin receptor Proteins 0.000 description 13
- 101001098557 Homo sapiens Proteinase-activated receptor 3 Proteins 0.000 description 13
- 101001051166 Homo sapiens Transcriptional activator MN1 Proteins 0.000 description 13
- 102100028139 Oxytocin receptor Human genes 0.000 description 13
- 102100037133 Proteinase-activated receptor 3 Human genes 0.000 description 13
- 102100024592 Transcriptional activator MN1 Human genes 0.000 description 13
- 238000007792 addition Methods 0.000 description 13
- 230000000295 complement effect Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 210000001778 pluripotent stem cell Anatomy 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 208000014674 injury Diseases 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 101150043847 FOXD1 gene Proteins 0.000 description 11
- 102100037057 Forkhead box protein D1 Human genes 0.000 description 11
- 230000004069 differentiation Effects 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 238000001356 surgical procedure Methods 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 238000013537 high throughput screening Methods 0.000 description 10
- 210000001161 mammalian embryo Anatomy 0.000 description 10
- 125000003835 nucleoside group Chemical group 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 201000004384 Alopecia Diseases 0.000 description 9
- 108700011259 MicroRNAs Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000003414 extremity Anatomy 0.000 description 9
- 210000004209 hair Anatomy 0.000 description 9
- 210000004962 mammalian cell Anatomy 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000008672 reprogramming Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 210000001109 blastomere Anatomy 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 210000004602 germ cell Anatomy 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 108091006086 inhibitor proteins Proteins 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 101000844686 Homo sapiens Thioredoxin reductase 1, cytoplasmic Proteins 0.000 description 7
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 230000003676 hair loss Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 230000036573 scar formation Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 6
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 241000283984 Rodentia Species 0.000 description 6
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 6
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 150000003833 nucleoside derivatives Chemical class 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 101000804811 Homo sapiens WD repeat and SOCS box-containing protein 1 Proteins 0.000 description 5
- 102100035334 WD repeat and SOCS box-containing protein 1 Human genes 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000002639 bone cement Substances 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 210000003953 foreskin Anatomy 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 108091027963 non-coding RNA Proteins 0.000 description 5
- 102000042567 non-coding RNA Human genes 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000007423 screening assay Methods 0.000 description 5
- 210000002536 stromal cell Anatomy 0.000 description 5
- 210000003437 trachea Anatomy 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 101000844683 Mus musculus Thioredoxin reductase 1, cytoplasmic Proteins 0.000 description 4
- 101000835089 Mus musculus Transferrin receptor protein 1 Proteins 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 210000004504 adult stem cell Anatomy 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 210000002459 blastocyst Anatomy 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000011194 good manufacturing practice Methods 0.000 description 4
- 230000003779 hair growth Effects 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000001503 joint Anatomy 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 230000037314 wound repair Effects 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 3
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 3
- 101000613490 Homo sapiens Paired box protein Pax-3 Proteins 0.000 description 3
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 3
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 3
- 102100040891 Paired box protein Pax-3 Human genes 0.000 description 3
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000010478 bone regeneration Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000009456 molecular mechanism Effects 0.000 description 3
- 210000000472 morula Anatomy 0.000 description 3
- 210000002198 morula cell Anatomy 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000010449 nuclear transplantation Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000001776 parthenogenetic effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000003239 periodontal effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000000515 tooth Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000269332 Ambystoma mexicanum Species 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101000998027 Homo sapiens Keratin, type I cytoskeletal 17 Proteins 0.000 description 2
- 102100033511 Keratin, type I cytoskeletal 17 Human genes 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 108010047357 Luminescent Proteins Proteins 0.000 description 2
- 102000006830 Luminescent Proteins Human genes 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 101150064238 TR gene Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 241000397921 Turbellaria Species 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000005786 degenerative changes Effects 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000002242 embryoid body Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003372 endocrine gland Anatomy 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000004709 eyebrow Anatomy 0.000 description 2
- 210000000720 eyelash Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 230000008175 fetal development Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000008186 parthenogenesis Effects 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009237 prenatal development Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000003813 thin hair Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000009772 tissue formation Effects 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- ZYJSTSMEUKNCEV-UHFFFAOYSA-N 3-diazo-1-diazonioprop-1-en-2-olate Chemical group [N-]=[N+]=CC(=O)C=[N+]=[N-] ZYJSTSMEUKNCEV-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000242759 Actiniaria Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000258957 Asteroidea Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108091005944 Cerulean Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 108091005942 ECFP Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 101000809594 Escherichia coli (strain K12) Shikimate kinase 1 Proteins 0.000 description 1
- 241000289695 Eutheria Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101001051973 Homo sapiens Fibroblast growth factor 23 Proteins 0.000 description 1
- 101000714378 Homo sapiens Neuron-specific vesicular protein calcyon Proteins 0.000 description 1
- 101000604110 Homo sapiens Palmitoleoyl-protein carboxylesterase NOTUM Proteins 0.000 description 1
- 101001134801 Homo sapiens Protocadherin beta-2 Proteins 0.000 description 1
- 101000863692 Homo sapiens Ski oncogene Proteins 0.000 description 1
- 101100377175 Homo sapiens ZNF280D gene Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101150068172 NAALADL1 gene Proteins 0.000 description 1
- 206010028885 Necrotising fasciitis Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102000014413 Neuregulin Human genes 0.000 description 1
- 108050003475 Neuregulin Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102100036421 Neuron-specific vesicular protein calcyon Human genes 0.000 description 1
- 241001195348 Nusa Species 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 101150067735 PCDHB17 gene Proteins 0.000 description 1
- 101150031894 PCDHB2 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100038424 Palmitoleoyl-protein carboxylesterase NOTUM Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100033437 Protocadherin beta-2 Human genes 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 101150058621 SIX1 gene Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102100029969 Ski oncogene Human genes 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010076818 TEV protease Proteins 0.000 description 1
- 101150091574 TRIM4 gene Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000006682 Warburg effect Effects 0.000 description 1
- 101150103037 ZNF280D gene Proteins 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 210000001909 alveolar process Anatomy 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000034127 bone morphogenesis Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000007348 cell dedifferentiation Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008709 cellular rearrangement Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 108010082025 cyan fluorescent protein Proteins 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000001705 ectoderm cell Anatomy 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- JOXWSDNHLSQKCC-UHFFFAOYSA-N ethenesulfonamide Chemical compound NS(=O)(=O)C=C JOXWSDNHLSQKCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 210000002082 fibula Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003661 hair follicle regeneration Effects 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000001096 hypoplastic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000001613 integumentary system Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000000111 isothermal titration calorimetry Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 108091007426 microRNA precursor Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 201000007970 necrotizing fasciitis Diseases 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000001982 neural crest cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 210000004663 osteoprogenitor cell Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 238000012831 peritoneal equilibrium test Methods 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000671 polyethylene glycol diacrylate Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000012636 positron electron tomography Methods 0.000 description 1
- 238000012877 positron emission topography Methods 0.000 description 1
- 230000006551 post-translational degradation Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 201000005380 purpura fulminans Diseases 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012713 reactive precursor Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000037309 reepithelialization Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000002982 water resistant material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 230000010388 wound contraction Effects 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Description
cGMP − 現行医薬品適正製造基準
CNS − 中枢神経系
DMEM − ダルベッコ改変イーグル培地
DMSO − ジメチルスルホキシド
DPBS − ダルベッコリン酸緩衝生理食塩水
EC − 胎生期癌
EC細胞 − 胎生期癌細胞;hEC細胞は、ヒト胎生期癌細胞である。
ECM − 細胞外マトリックス
ED細胞 − 胚由来細胞;hED細胞は、ヒトED細胞である。
EDTA − エチレンジアミン四酢酸
EG細胞 − 胚性生殖細胞;hEG細胞は、ヒトEG細胞である。
ES細胞 − 胚性幹細胞;hES細胞は、ヒトES細胞である。
FACS − 蛍光活性化細胞選別
FBS − ウシ胎仔血清
GMP − 医薬品適正製造基準
hED細胞 − ヒト胚由来細胞
hEG細胞 − ヒト胚性生殖細胞は、胎児組織の始原生殖細胞から誘導される幹細胞である。
hiPS細胞 − ヒト人工多能性幹細胞は、SOX2、KLF4、OCT4、MYC、またはNANOG、LIN28、OCT4、およびSOX2などのhES特異的転写因子への曝露後に体細胞から得られるhES細胞と類似する特性を有する細胞である。
HSE − ヒト皮膚等価物は、細胞と、試験目的のため、または創傷修復の促進における治療適用のために製造された生物学的または合成マトリックスとの混合物である。
ICM − 哺乳動物胚盤胞段階の胚の内部細胞塊。
iPS細胞 − 人工多能性幹細胞は、SOX2、KLF4、OCT4、MYC、またはNANOG、LIN28、OCT4、およびSOX2などのES特異的転写因子への曝露後に体細胞から得られるhES細胞と類似する特性を有する細胞である。
iTR − 誘導組織再生
LOH − ヘテロ接合性の喪失
MEM − 最少必須培地
NT − 核移植
PBS − リン酸緩衝生理食塩水
PNS − 末梢神経系
PS線維芽細胞 − 瘢痕形成前線維芽細胞は、妊娠初期の皮膚から誘導されるか、またはED細胞が瘢痕形成なしに皮膚創傷の迅速な治癒を促進する点で出生前パターンの遺伝子発現を示すED細胞から誘導される線維芽細胞である。
RFU − 相対蛍光単位
SCNT − 体細胞核移植
SFM − 無血清培地
TR − 組織再生
用語「分析的再プログラミング技術」とは、体細胞の遺伝子発現パターンを、iPS、ES、ED、ECまたはEG細胞のものなどの、より多能性の高い状態のものに再プログラミングするための様々な方法を指し、再プログラミングは、複数の個別のステップで起こり、体細胞の卵母細胞への移植およびその卵母細胞の活性化に単に依るものではない(それぞれの開示が参照により本明細書に組み込まれる、2001年11月26日に出願された米国特許出願第60/332,510号;2002年11月26日に出願された同第10/304,020号;2003年11月26日に出願されたPCT出願PCT/US02/37899;2005年8月3日に出願された米国特許出願第60/705625号;2005年8月20日に出願された米国特許出願第60/729173号;2006年7月5日に出願された米国特許出願第60/818813号、2006年8月3日に出願されたPCT/US06/30632を参照されたい)。
本発明は、胚性期においてTRを授ける遺伝子発現パターンが失われた、ヒトなどの哺乳動物種における発生の胎児、新生児、幼児、または成体期において体細胞iTRを実施するのに有用な化合物、組成物、および方法を提供する。一態様において、本発明は、霊長類種、より特には、ヒト種を含む哺乳動物種においてTRを調節する遺伝子を同定する方法を提供し、ここで、前記遺伝子は、発生の胎児および成体段階と比較して発生の胚性段階で示差的に発現される、mRNAおよび非コードRNAまたは前記RNA中のスプライスバリアントをコードする遺伝子の発現を比較することにより同定される。より特には、前記方法は、胎児および成体細胞(胚から胎児発生への転移点の後)と比較して、発生の出生前段階、特に、発生の胚性期(胚から胎児発生への転移点の前)において複数の多様な体細胞型中で示差的に発現されるmRNAおよび非コードRNAをコードする遺伝子を同定する。ヒト種の場合、胚から胎児発生への転移は、出生前発生の約8週で起こり、マウスにおいては、それは約16日で起こり、ラット種においては、約17.5日で起こる。
本発明は、iTRモジュレータおよびその使用方法を提供する。本発明は、iTRモジュレータを同定するのに有用な組成物および方法をさらに提供する。いくつかの態様において、本発明は、前記iTRモジュレータの濃度を変化させる薬剤を、それを必要とする多細胞生物に投与することを含む、再生を増強する方法を提供する。
本発明は、発現が、COX7A1などの本明細書に記載のTR活性化因子遺伝子の1つにより駆動されるGFPなどのマーカーを含む(a)リポーター分子を用いてiTR因子を同定するための方法を提供する。本発明は、試験化合物がTR活性化因子遺伝子の発現に影響するかどうか、および/またはTR阻害遺伝子の発現を阻害するかどうかを決定することを含むスクリーニングアッセイを提供する。本発明はさらに、前記方法を実行するのに有用なリポーター分子および組成物を提供する。一般に、本発明の方法を用いて同定される化合物は、それぞれ、TR活性化因子または阻害因子の増加または減少をもたらす任意の機構によって作用することができる。
一般に、本発明のリポーター分子において有用な検出部分としては、検出可能な蛍光、化学発光、または生物発光シグナルを生成またはクエンチする光放出または光吸収化合物が挙げられる。いくつかの実施形態においては、TR活性化因子遺伝子の活性化またはTR阻害遺伝子の阻害は、液体媒体中への検出部分の放出を引き起こし、媒体(またはその試料)中に存在する放出された検出部分により生成またはクエンチされたシグナルが検出される。いくつかの実施形態においては、得られるシグナルは、検出部分の特性の変化を引き起こし、そのような変化は、例えば、光シグナルとして検出することができる。例えば、シグナルは、検出部分によって電磁放射(例えば、スペクトルの赤外部、可視部もしくはUV部内の波長を有する放射)の放出または吸収を変化させることができる。いくつかの実施形態においては、リポーター分子は蛍光または発光部分を含み、第2の分子は蛍光または発光部分をクエンチするクエンチャーとして働く。そのような変化を、当業界で公知の装置および方法を用いて検出することができる。
TR活性化因子およびTR阻害因子の遺伝子を、図1に列挙する。本発明の方法において有用なTR活性化因子およびTR阻害因子ポリペプチドを、様々な方法により取得することができる。いくつかの実施形態においては、ポリペプチドを、組換えDNA技術を用いて生成する。組換えタンパク質発現のための標準的な方法を用いることができる。TR活性化因子またはTR阻害因子遺伝子をコードする核酸を、例えば、該遺伝子を発現する細胞から(例えば、PCRもしくは他の増幅方法によるか、またはクローニングによる)、または化学的合成、もしくはcDNA配列ポリペプチド配列に基づくin vitroでの転写により容易に取得することができる。当業者であれば、遺伝子コードの縮重性のため、遺伝子は多くの異なる核酸配列によってコードされていてもよいことを知っているであろう。場合により、配列は、選択される宿主細胞中での発現のためにコドン最適化される。遺伝子を、細菌、真菌、動物、もしくは植物細胞または生物中で発現させることができる。遺伝子を、それを天然で発現する細胞から、またはタンパク質をコードする核酸が一過的もしくは安定に導入された細胞、例えば、遺伝子をコードする発現ベクターを含有する細胞から単離することができる。いくつかの実施形態においては、遺伝子は、培養物中の細胞により分泌され、培養培地から単離される。
様々な試験化合物を、iTR因子を同定するための本発明の方法において用いることができる。例えば、試験化合物は、低分子、ポリペプチド、ペプチド、核酸、オリゴヌクレオチド、脂質、炭水化物、抗体、またはハイブリッド分子であってもよい。化合物を、天然の供給源から取得するか、または合成的に生成することができる。化合物は、少なくとも部分的に純粋であってもよいか、または成分が少なくとも一部未知であるか、もしくは特徴付けられていない抽出物もしくは他の種類の混合物中に存在してもよい。抽出物またはその画分を、例えば、植物、動物、微生物、海洋生物、発酵培養液(例えば、土壌、細菌または真菌発酵培養液)などから生成することができる。いくつかの実施形態においては、化合物コレクション(「ライブラリー」)を用いる。ライブラリーは、例えば、100〜500,000の化合物、またはそれ以上を含んでもよい。化合物はマルチウェルプレート(例えば、384ウェルプレート、1596ウェルプレートなど)中に配置されることが多い。それらを溶媒(例えば、DMSO)中に溶解するか、または乾燥形態で、例えば、粉末もしくは固体として提供することができる。合成、半合成、および/または天然の化合物のコレクションを試験することができる。化合物ライブラリーは、構造的に関連する、構造的に異なる、または構造的に関連しない化合物を含んでもよい。化合物は、人工のもの(ヒトにより発明された構造を有し、自然には見出されない)または天然のものであってもよい。いくつかの実施形態においては、ライブラリーは、他の薬物探索プログラムにおいて「ヒット」もしくは「リード」として同定された少なくともいくつかの化合物および/またはその誘導体を含む。化合物ライブラリーは、天然の生成物および/または非指向的もしくは指向的合成有機化学を用いて作成された化合物を含んでもよい。化合物ライブラリーは、低分子ライブラリーであることが多い。対象となる他のライブラリーとしては、ペプチドまたはペプトイドライブラリー、cDNAライブラリー、抗体ライブラリー、およびオリゴヌクレオチドライブラリーが挙げられる。ライブラリーは、焦点を合わせたものであってもよい(例えば、同じコア構造を有する、同じ前駆体から誘導される、または少なくとも1つの共通の生化学的活性を有する化合物から主に構成される)。
上記の様々な本発明のスクリーニングアッセイは、試験化合物が活性なTR阻害因子のレベルを阻害するか、または活性なTR活性化因子のレベルを増加させるかどうかを決定することを含む。リポーター分子の発現のための好適な細胞は、上記の通りである。
医薬組成物
iTR因子は、様々な異なる使用を有する。そのような使用の非限定例は、本明細書で考察される。いくつかの実施形態においては、iTR因子は、臓器または組織の再生を増強するために用いられる。増強された再生にとって好適な臓器および組織の例としては、手足、指、軟骨、心臓、血管、骨、食道、胃、肝臓、胆嚢、膵臓、腸、直腸、肛門、内分泌腺(例えば、甲状腺、副甲状腺、副腎、膵臓の内分泌部)、皮膚、毛包、胸腺、脾臓、骨格筋、局所的に損傷した心筋、平滑筋、脳、脊髄、末梢神経、卵巣、卵管、子宮、膣、乳腺、精巣、精管、精嚢、前立腺、陰茎、咽頭、喉頭、気管、気管支、肺、腎臓、尿管、膀胱、尿道、眼(例えば、網膜、角膜)、または耳(例えば、コルチ器官)が挙げられる。いくつかの実施形態においては、iTR因子は、間質層、例えば、組織の柔組織を支持する結合組織の再生を増強するために用いられる。いくつかの実施形態においては、iTR因子は、手術、例えば、疾患を有するか、もしくは損傷した組織、臓器、または手足、指などの他の構造の少なくとも一部の除去を必要とする手術の後の再生を増強するために用いられる。例えば、そのような手術は、肝臓、肺、腎臓、胃、膵臓、腸、乳腺、卵巣、精巣、骨、手足、指、筋肉、皮膚などの少なくとも一部を除去するものであってもよい。いくつかの実施形態においては、手術は、腫瘍を除去するためのものである。いくつかの実施形態においては、iTR因子は、外傷、手術、疾患、および熱傷の後の皮膚の傷を残さない再生を促進するために用いられる。
本発明のある特定の実施形態は、図1中の1つもしくは複数の遺伝子または図1中の遺伝子によりコードされる1つもしくは複数の遺伝子産物を含むキットを提供する。一実施形態において、キットは、PCDHHB2、PCDHB17、Nbla10527、RAB3IP、DLX1、DRD11P、FOXD1、LOC728755、AFF3、F2RL2、MN1、CBCAQH03 5、LOC791120、SIX1、OXTR、およびWSB1から選択される遺伝子または1つもしくは複数の遺伝子によりコードされる遺伝子産物を含む。他の実施形態においては、キットは、COMT、TRIM4、CAT、PSMD、SHMT、LOC205251、ZNF280D、S100A6、MGMT、ZNF280D、DYNLT3、NAALADL1、COX7A1、TSPYL5、IAH1、C18orf56、RPS7、FDPS、ELOVL6、INSIG1、ACAT2、およびMAOAから選択される遺伝子または1つもしくは複数の遺伝子によりコードされる遺伝子産物を含む。さらに他の実施形態において、キットは、PCDHHB2、PCDHB17、Nbla10527、RAB3IP、DLX1、DRD11P、FOXD1、LOC728755、AFF3、F2RL2、MN1、CBCAQH03 5、LOC791120、SKI、OXTR、およびWSB1から選択される遺伝子または複数の遺伝子によりコードされる遺伝子産物を含む。さらなる実施形態において、キットは、COMT、TRIM4、CAT、PSMD、SHMT、LOC205251、ZNF280D、S100A6、MGMT、ZNF280D、DYNLT3、NAALADLl、COX7A1、TSPYL5、IAH1、C18orf56、RPS7、FDPS、ELOVL6、INSIG1、ACAT2、およびMAOAから選択される遺伝子または複数の遺伝子によりコードされる遺伝子産物を含む。
以下に記載の方法に加えて、傷を残さない再生能力に対応する遺伝子発現の胚性パターンを有する細胞の生成および使用において有用な方法を、「Novel Uses of Cells With Prenatal Patterns of Gene Expression」の表題の2006年4月11日に出願されたPCT出願PCT/US2006/013519;「Methods to Accelerate the Isolation of Novel Cell Strains from Pluripotent Stem Cells and Cells Obtained Thereby」の表題の2006年11月21日に出願された米国特許出願第11/604,047号;および「Methods to Accelerate the Isolation of Novel Cell Strains from Pluripotent Stem Cells and Cells Obtained Thereby」の表題の2009年7月16日に出願された米国特許出願第12/504,630号に見出すことができ、それぞれその全体が参照により本明細書に組み込まれる。
HyStem−C(BioTime、Alameda、CA、USA)を、製造業者の説明書に従って再構成させる。簡単に述べると、HyStem成分(チオール改変ヒアルロナン、10mg)を、約20分かけて1.0mlの脱気した脱イオン水に溶解して、1%w/v溶液を調製する。Gelin−S成分(チオール改変ゼラチン、10mg)を、1mlの脱気した脱イオン水に溶解して、1%w/v溶液を調製し、PEGDA(PEGジアクリレート、10mg)を、0.5mlの脱気した脱イオン水に溶解して、2%w/v溶液を調製する。次いで、HyStem(1ml、1%w/v)を、使用直前にGelin−S(1ml、1%w/v)と混合する。ペレット化された細胞を、上記の最近調製されたHyStem:Gelin−s(1:1v/v)ミックス中に再懸濁する。架橋剤PEGDA、2.0×107細胞/mlの最終濃度の細胞懸濁液の添加の際に、細胞/マトリックス組合せを標的組織中に注入する。
例えば、限定されるものではないが、dsRNAを、フランキングするT7プロモーターを含むPCR生成鋳型を用いてin vitroでの転写反応(Promega)から調製し、フェノール抽出およびエタノール沈降により精製し、水中での再懸濁後にアニーリングする。無傷の実験動物に、手術の2時間後に1回目の注入から開始する誘導組織傷害後、3日連続で30nLのdsRNAを4回注入する。
hES、iPS、およびクローンEP細胞株中での遺伝子発現を、多様な胎児および成体由来体細胞型と比較することによるiTR遺伝子の同定
Illumina遺伝子発現マイクロアレイ分析を、14の多様な血液細胞型、3つ全ての胚葉に由来する115の多様な胎児および成体由来体細胞型、545の多様なクローンhES由来およびiPS由来EP細胞株、12のhES細胞株ならびに17のヒトiPS細胞株を含む、多様な成体および胚細胞型において実施した。胎児/成体由来細胞中の各プローブの平均RFU値を、クローンEP細胞株中での対応する平均と比較し、2セットのうちの1つにおける比較的均一により高い発現を示すプローブを同定した。図1、および図2〜15に示されるように、これらの遺伝子は、酸化的リン酸化(COX7A1)における公知の役割を有する因子、SIX1およびDLX1として、ならびに細胞内での他の多様な活性を有する転写因子である。100の値より下のRFU値は、バックグラウンドシグナル(すなわち、検出可能な発現がない)と考えられる。
トランスジェニックマウスにおけるiTR遺伝子の改変および成体動物におけるiTRに関するアッセイ。
遺伝子:CAT、COMT、COX7A1、DLX1、DRD1IP、LOC205251 NAALADL1、PCDHB2、PCDHB17、原発性神経芽腫cDNA、クローン:Nbla10527、RAB3IP、SIX1、TRIM4、およびZNF280Dの発現の胚性パターンを、個別に誘導するか、または切開された耳たぶおよび他の体細胞組織中での組織再生の増加に対するその効果を実証するために組み合わせて誘導する。
iTR遺伝子のモジュレーションによるヒト間質組織再生のin vitroアッセイ。
iTR誘導遺伝子を上方調節するか、またはiTR阻害遺伝子を下方調節する再生能力を、本明細書に記載のin vitro創傷修復アッセイを用いてアッセイすることができる。簡単に述べると、スクラッチテストを記載のように用いた(Nature Protocols 2、329〜333頁(2007) Liang CCら、「In vitro scratch assay:a convenient and inexpensive method for analysis of cell migration in vitro」)。このアッセイは、本明細書に記載の他の胎児および成体由来間質細胞と同等のレベルでCOX7A1を発現するヒト新生児包皮線維芽細胞(Xgene Corp、Sausalito CA)を用いた。線維芽細胞を、0.1%ゼラチンで予め被覆された6ウェルプレート中で培養された10%FBSを添加したDMEM培地を用いて集密となるまで増殖させた後、加湿されたインキュベータ中、5%O2および10%CO2と共に培養した。
− SMARTpool:ON−TARGETplus COX7A1 siRNA、5nmole(Dharmacon、カタログ番号L−013152−02−0005)
− ON−TARGETplus非標的化プール、5nmole(Dharmacon、カタログ番号D−001810−10−05)
− DharmaFECT1トランスフェクション試薬、0.75mL(Dharmacon、カタログ番号T−2001−02)
− 無血清、無抗生物質の基本培地
− 無抗生物質完全培地。
Claims (23)
- COX7A1を阻害する1つまたは複数の薬剤を含む、対象において創傷治癒を増強するための医薬組成物であって、前記COX7A1を阻害する1つまたは複数の薬剤が、
COX7A1を標的とするRNAi剤、COX7A1を標的とするアンチセンスオリゴヌクレオチド、COX7A1を標的とする阻害抗体、及びCOX7A1遺伝子の発現を阻害するリボザイム及び三本鎖核酸からなる群から選択され、
前記RNAi剤は、(a)siRNA、(b)二本鎖RNA、(c)shRNA、(d)miRNA前駆体、及び(e)前記siRNA、二本鎖RNA、shRNA、又はmiRNA前駆体をコードするプラスミド及びウイルスベクターからなる群から選択される、医薬組成物。 - 対象が哺乳動物である、請求項1に記載の医薬組成物。
- 哺乳動物がヒトである、請求項2に記載の医薬組成物。
- 創傷の部位に投与される、請求項1から3のいずれか一項に記載の医薬組成物。
- 対象に投与することにより、投与部位でACTA2およびCOL1A1遺伝子の発現が阻害される、請求項1から4のいずれか一項に記載の医薬組成物。
- COMT、TRIM4、CAT、PSMD、SHMT、LOC205251、ZNF280D、S100A6、MGMT、DYNLT3、NAALADLl、TSPYL5、IAH1、C18orf56、RPS7、FDPS、ELOVL6、INSIG1、ACAT2、およびMAOAから選択される1つまたは複数の遺伝子または遺伝子産物を阻害する1つまたは複数の薬剤をさらに含む、請求項1から5のいずれか一項に記載の医薬組成物。
- COMT、TRIM4、CAT、PSMD、SHMT、LOC205251、ZNF280D、S100A6、MGMT、DYNLT3、NAALADLl、TSPYL5、IAH1、C18orf56、RPS7、FDPS、ELOVL6、INSIG1、ACAT2、およびMAOAから選択される1つまたは複数の遺伝子または遺伝子産物を阻害する1つまたは複数の薬剤が核酸またはタンパク質である、請求項6に記載の医薬組成物。
- (a)核酸がRNA;(b)核酸が二本鎖RNA、siRNA、shRNA、またはmiRNA前駆体;もしくは(c)タンパク質が抗体である、請求項7に記載の医薬組成物。
- 溶液である、請求項1から8のいずれか一項に記載の医薬組成物。
- in situでヒドロゲルを形成する1つまたは複数の化合物をさらに含む、請求項1から9のいずれか一項に記載の医薬組成物。
- ヒドロゲルがヒアルロン酸含有ヒドロゲルまたはヒアルロン酸及びコラーゲンI含有ヒドロゲルである、請求項10に記載の医薬組成物。
- 1つまたは複数の細胞、テロメラーゼの触媒成分を発現するベクター、または1つまたは複数の細胞とテロメラーゼの触媒成分を発現するベクターの両方をさらに含む、請求項1から11のいずれか一項に記載の医薬組成物。
- 1つまたは複数の細胞が、前駆細胞または分化した細胞である、請求項12に記載の医薬組成物。
- 前駆細胞または分化した細胞が、間葉前駆細胞、神経前駆細胞、内皮前駆細胞、毛包前駆細胞、神経堤前駆細胞、乳腺幹細胞、肺前駆細胞、筋肉前駆細胞、脂肪由来前駆細胞、上皮前駆細胞、造血前駆細胞、軟骨細胞、骨芽細胞、ケラチノサイト、肝細胞、筋芽細胞、またはそれらのいずれかの組合せである、請求項13に記載の医薬組成物。
- COX7A1を阻害する1つまたは複数の薬剤を含む、対象において創傷治癒を増強するためのキットであって、前記COX7A1を阻害する1つまたは複数の薬剤が、
COX7A1を標的とするRNAi剤、COX7A1を標的とするアンチセンスオリゴヌクレオチド、COX7A1を標的とする阻害抗体、及びCOX7A1遺伝子の発現を阻害するリボザイム及び三本鎖核酸からなる群から選択され、
前記RNAi剤は、(a)siRNA、(b)二本鎖RNA、(c)shRNA、(d)miRNA前駆体、及び(e)前記siRNA、二本鎖RNA、shRNA、又はmiRNA前駆体をコードするプラスミド及びウイルスベクターからなる群から選択される、キット。 - COMT、TRIM4、CAT、PSMD、SHMT、LOC205251、ZNF280D、S100A6、MGMT、DYNLT3、NAALADLl、TSPYL5、IAH1、C18orf56、RPS7、FDPS、ELOVL6、INSIG1、ACAT2、およびMAOAから選択される1つまたは複数の遺伝子または遺伝子産物を阻害する1つまたは複数の薬剤をさらに含む、請求項15に記載のキット。
- COMT、TRIM4、CAT、PSMD、SHMT、LOC205251、ZNF280D、S100A6、MGMT、DYNLT3、NAALADLl、TSPYL5、IAH1、C18orf56、RPS7、FDPS、ELOVL6、INSIG1、ACAT2、およびMAOAから選択される1つまたは複数の遺伝子または遺伝子産物を阻害する1つまたは複数の薬剤が核酸またはタンパク質である、請求項16に記載のキット。
- (a)核酸がRNA;(b)核酸が二本鎖RNA、siRNA、shRNA、またはmiRNA前駆体;もしくは(c)タンパク質が抗体である、請求項17に記載のキット。
- in situにおいてヒドロゲルを形成する1つまたは複数の化合物をさらに含む、請求項15から18のいずれか一項に記載のキット。
- ヒドロゲルが、ヒアルロン酸含有ヒドロゲルまたはヒアルロン酸及びコラーゲンI含有ヒドロゲルである、請求項19に記載のキット。
- 1つまたは複数の細胞、テロメラーゼの触媒成分を発現しているベクター、または1つまたは複数の細胞とテロメラーゼの触媒成分を発現しているベクターとの両方をさらに含む、請求項15から20のいずれか一項に記載のキット。
- 1つまたは複数の細胞が、前駆細胞または分化した細胞である、請求項21に記載のキット。
- 前駆細胞または分化した細胞が、間葉前駆細胞、神経前駆細胞、内皮前駆細胞、毛包前駆細胞、神経堤前駆細胞、乳腺幹細胞、肺前駆細胞、筋肉前駆細胞、脂肪由来前駆細胞、上皮前駆細胞、造血前駆細胞、軟骨細胞、骨芽細胞、ケラチノサイト、肝細胞、筋芽細胞、またはそれらのいずれかの組合せである、請求項22に記載のキット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361831421P | 2013-06-05 | 2013-06-05 | |
US61/831,421 | 2013-06-05 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016518393A Division JP6529486B2 (ja) | 2013-06-05 | 2014-06-03 | 哺乳動物種における誘導組織再生のための組成物および方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020209201A Division JP2021054846A (ja) | 2013-06-05 | 2020-12-17 | 哺乳動物種における誘導組織再生のための組成物および方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019163295A JP2019163295A (ja) | 2019-09-26 |
JP2019163295A5 JP2019163295A5 (ja) | 2020-02-20 |
JP6821908B2 true JP6821908B2 (ja) | 2021-01-27 |
Family
ID=52008522
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016518393A Active JP6529486B2 (ja) | 2013-06-05 | 2014-06-03 | 哺乳動物種における誘導組織再生のための組成物および方法 |
JP2019091651A Active JP6821908B2 (ja) | 2013-06-05 | 2019-05-14 | 哺乳動物種における誘導組織再生のための組成物および方法 |
JP2020209201A Pending JP2021054846A (ja) | 2013-06-05 | 2020-12-17 | 哺乳動物種における誘導組織再生のための組成物および方法 |
JP2022075775A Pending JP2022105142A (ja) | 2013-06-05 | 2022-05-02 | 哺乳動物種における誘導組織再生のための組成物および方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016518393A Active JP6529486B2 (ja) | 2013-06-05 | 2014-06-03 | 哺乳動物種における誘導組織再生のための組成物および方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020209201A Pending JP2021054846A (ja) | 2013-06-05 | 2020-12-17 | 哺乳動物種における誘導組織再生のための組成物および方法 |
JP2022075775A Pending JP2022105142A (ja) | 2013-06-05 | 2022-05-02 | 哺乳動物種における誘導組織再生のための組成物および方法 |
Country Status (7)
Country | Link |
---|---|
US (3) | US10961531B2 (ja) |
EP (2) | EP3003290B1 (ja) |
JP (4) | JP6529486B2 (ja) |
CN (2) | CN105473134B (ja) |
AU (3) | AU2014275130B2 (ja) |
CA (1) | CA2914615C (ja) |
WO (1) | WO2014197421A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10961531B2 (en) | 2013-06-05 | 2021-03-30 | Agex Therapeutics, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
AU2017278931B2 (en) * | 2016-06-07 | 2023-06-29 | Agex Therapeutics, Inc. | Improved methods for detecting and modulating the embryonic-fetal transition in mammalian species |
US11331373B2 (en) | 2017-02-10 | 2022-05-17 | St. Jude Children's Research Hospital | Combination therapy for treating disorders of the ear |
CN112955141A (zh) | 2018-04-23 | 2021-06-11 | Agex治疗公司 | 用于在哺乳动物细胞中诱导组织再生和衰老细胞裂解的改善方法 |
WO2020198696A1 (en) * | 2019-03-28 | 2020-10-01 | Agex Therapeutics, Inc. | Induced tissue regeneration using extracellular vesicles |
EP4301400A1 (en) * | 2021-03-02 | 2024-01-10 | Reverse Bioengineering, Inc. | Methods and compositions used to modify chromatin architecture to regulate phenotype in aging and cancer |
CA3235464A1 (en) * | 2021-10-15 | 2023-04-20 | Reverse Bioengineering, Inc. | Methods for modulating the regenerative phenotype in mammalian cells |
CN116171942A (zh) * | 2023-03-10 | 2023-05-30 | 四川大学 | 一种six1基因干扰构建涡虫视神经系统缺失模型的方法 |
Family Cites Families (142)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2197915B (en) | 1986-11-19 | 1990-11-14 | Rolls Royce Plc | Improvements in or relating to fluid bearings |
US5686306A (en) | 1992-05-13 | 1997-11-11 | Board Of Regents, The University Of Texas System | Methods and reagents for lengthening telomeres |
US5639613A (en) | 1992-05-13 | 1997-06-17 | Board Of Regents, University Of Texas System | Methods for cancer diagnosis and prognosis |
US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5922601A (en) | 1995-01-19 | 1999-07-13 | Biotransplant, Inc. | High efficiency gene trap selection of regulated genetic loci |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
JP2001508302A (ja) | 1997-01-10 | 2001-06-26 | ライフ テクノロジーズ,インコーポレイテッド | 胚性幹細胞血清置換 |
NO971997D0 (no) | 1997-04-29 | 1997-04-29 | Kjetil Tasken | Bruk av immunmodulerende midler |
FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
US5986020A (en) | 1997-08-05 | 1999-11-16 | Campbell; J. David | Process for producing hyperbranched polymers |
CA2307807C (en) | 1997-10-23 | 2008-09-02 | Andrea G. Bodnar | Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture |
US20020051762A1 (en) | 1998-01-23 | 2002-05-02 | Shahin Rafii | Purified populations of endothelial progenitor cells |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
US6248934B1 (en) | 1998-10-26 | 2001-06-19 | The Regents Of The University Of California | Gene trap vectors |
DE60001229T2 (de) | 1999-04-09 | 2003-10-30 | Smithkline Beecham Corp | Triarylimidazole |
US20040199935A1 (en) | 1999-06-30 | 2004-10-07 | Chapman Karen B. | Cytoplasmic transfer to de-differentiate recipient cells |
JP2003503071A (ja) | 1999-06-30 | 2003-01-28 | アドバンスド セル テクノロジー、インコーポレイテッド | 脱分化レシピエント細胞への細胞質移入 |
US20030161817A1 (en) | 2001-03-28 | 2003-08-28 | Young Henry E. | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
EP1218603B1 (en) | 1999-10-07 | 2003-05-21 | Consolidated Minerals, Inc | System and method for making wallboard or backerboard sheets including aerated concrete |
IL149175A0 (en) | 1999-10-28 | 2002-11-10 | Univ Massachusetts | Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
US20030129745A1 (en) | 1999-10-28 | 2003-07-10 | Robl James M. | Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
US6280718B1 (en) | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
US6602711B1 (en) | 2000-02-21 | 2003-08-05 | Wisconsin Alumni Research Foundation | Method of making embryoid bodies from primate embryonic stem cells |
AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
US7005252B1 (en) | 2000-03-09 | 2006-02-28 | Wisconsin Alumni Research Foundation | Serum free cultivation of primate embryonic stem cells |
GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
JP2004517068A (ja) | 2000-11-16 | 2004-06-10 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
GB0027987D0 (en) | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
US20020069484A1 (en) | 2000-11-28 | 2002-06-13 | Creel Greg S. | Rotatable handle structure for hand held tool |
US20020142397A1 (en) | 2000-12-22 | 2002-10-03 | Philippe Collas | Methods for altering cell fate |
EP1356035B1 (en) | 2000-12-22 | 2011-03-16 | Kyowa Hakko Kirin Co., Ltd. | Methods for cloning non-human mammals using reprogrammed donor chromatin or donor cells |
GB0102668D0 (en) | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
WO2002089658A2 (en) * | 2001-05-07 | 2002-11-14 | New York University | Microvascular free flaps for local or systemic delivery |
EP1420807A4 (en) | 2001-08-09 | 2005-08-17 | Cornell Res Foundation Inc | PROTECTION OF THE GROWTH FACTOR DERIVED FROM MYOCARDIAL PLAQUETTES |
US6887706B2 (en) | 2001-10-03 | 2005-05-03 | Wisconsin Alumni Research Foundation | Method of in vitro differentiation of transplantable neural precursor cells from primate embryonic stem cells |
JP4085062B2 (ja) | 2001-11-02 | 2008-04-30 | ウイスコンシン アラムニ リサーチ ファンデーション | 霊長類の胚性幹細胞から由来した内皮細胞 |
GB0127433D0 (en) | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
DE60233248D1 (de) | 2001-11-15 | 2009-09-17 | Childrens Medical Center | Verfahren zur isolierung, expansion und differenzierung fötaler stammzellen aus chorionzotte, fruchtwasser und plazenta und therapeutische verwendungen davon |
GB0127430D0 (en) | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
EP1456374A4 (en) | 2001-11-26 | 2005-08-17 | Advanced Cell Tech Inc | METHODS FOR THE PRODUCTION AND USE OF REPROGRAMME HUMAN SOMATIC CELL CORES AND AUTOLOGOUS AND ISOGENIC HUMAN STEM CELLS |
US20030180268A1 (en) | 2002-02-05 | 2003-09-25 | Anthony Atala | Tissue engineered construct for supplementing or replacing a damaged organ |
EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
AU2003214566A1 (en) | 2002-03-14 | 2003-09-22 | Anosys, Inc. | Functionalization of T cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions |
JP2005530800A (ja) | 2002-05-15 | 2005-10-13 | スミスクライン・ビーチャム・コーポレイション | ベンゾオキサジンおよびベンゾオキサジノン置換トリアゾール |
US20060003446A1 (en) | 2002-05-17 | 2006-01-05 | Gordon Keller | Mesoderm and definitive endoderm cell populations |
AU2003299509A1 (en) | 2002-06-21 | 2004-05-13 | University Of Utah Research Foundation | Crosslinked compounds and methods of making and using thereof |
AU2003286442A1 (en) | 2002-10-16 | 2004-05-04 | Advanced Cell Technology, Inc. | Methods using gene trapped stem cells for marking pathways of stem cell differentiation and making and isolating differentiated cells |
JP2006507841A (ja) * | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | 機能的siRNAおよび超機能的siRNA |
EP1596659A2 (en) | 2003-02-28 | 2005-11-23 | Duke University | Progenitor cells and methods of using same |
PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
EP1624935B1 (en) | 2003-05-15 | 2016-09-28 | The University of Utah Research Foundation | Anti-adhesion composites and methods os use thereof |
GB0326963D0 (en) | 2003-11-19 | 2003-12-24 | Glaxo Group Ltd | Compounds |
CA2549295C (en) | 2003-12-04 | 2016-05-03 | University Of Utah Research Foundation | Modified macromolecules and methods of making and using thereof |
CA2852122A1 (en) | 2004-01-02 | 2005-07-28 | Advanced Cell Technology, Inc. | Novel culture systems for ex vivo development |
RU2367661C2 (ru) | 2004-03-05 | 2009-09-20 | Тайсо Фармасьютикал Ко., Лтд. | Производные тиазола |
EP1737949B1 (en) | 2004-03-09 | 2010-09-15 | Absorber AB | Endothelial progenitor cells and methods of use thereof |
SG150567A1 (en) | 2004-03-23 | 2009-03-30 | Akaike Toshihiro | Pluripotent stem cell growing method |
US20080268429A1 (en) | 2004-06-02 | 2008-10-30 | Sourcepharm, Inc. | Rna - Containing Microvesicles and Methods Therefor |
US8021847B2 (en) | 2004-06-02 | 2011-09-20 | Proxy Life Science Holdings, Inc. | Microvesicle-based compositions and methods |
ITRM20040568A1 (it) | 2004-11-18 | 2005-02-18 | Uni Degli Studi Di Roma Tor Vergata | Uso della tecnica "phage display" per l'identificazione di peptidi con capacita' di legame a cellule staminali/progenitore, peptidi cosi' ottenuti e loro usi. |
EP2428563A1 (en) | 2005-02-10 | 2012-03-14 | Regents Of The University Of Minnesota | Vascular/lymphatic endothelial cells |
EP1860180A4 (en) | 2005-02-23 | 2009-03-11 | Found Biomedical Res & Innov | METHOD FOR IN VITRO AMPLIFICATION OF ENDOTHELIAL PROGENITOR CELL |
US20090215640A1 (en) | 2005-05-27 | 2009-08-27 | West Michael D | Methods for identifying ligands for stem cells and cells derived therefrom |
CA2650841A1 (en) | 2005-06-06 | 2006-12-14 | Suomen Punainen Risti, Veripalvelu | Method of profiling a cell population |
US20100158872A1 (en) | 2005-06-23 | 2010-06-24 | Mount Sinai School Of Medicine Of New York Univers | Cardiomyocyte Cell Populations |
EP1984487B1 (en) | 2005-08-03 | 2022-10-12 | Astellas Institute for Regenerative Medicine | Improved methods of reprogramming animal somatic cells |
US20090271335A1 (en) | 2005-10-20 | 2009-10-29 | Advanced Cell Technology, Inc. | Totipotent, Nearly Totipotent or Pluripotent Mammalian Cells Homozygous or Hemizygous for One or More Histocompatibility Antigent Genes |
WO2007062198A1 (en) | 2005-11-21 | 2007-05-31 | Advanced Cell Technology, Inc. | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby |
US20080070303A1 (en) | 2005-11-21 | 2008-03-20 | West Michael D | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby |
WO2007058671A1 (en) | 2005-11-21 | 2007-05-24 | West Michael D | Novel uses of cells with prenatal patterns of gene expression |
US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
KR20150072458A (ko) * | 2006-11-15 | 2015-06-29 | 코다 테라퓨틱스, 인크. | 상처 치유를 위한 개선 방법 및 조성물 |
NZ578728A (en) | 2007-01-09 | 2012-01-12 | Lead Pharma Cel Models Ip B V | Provision of new cardiomyocyte progenitor cells and cardiomyocytes derived therefrom |
WO2008089448A2 (en) | 2007-01-19 | 2008-07-24 | Cornell Presearch Foundation, Inc. | Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis |
CN101641436A (zh) | 2007-01-30 | 2010-02-03 | 佐治亚大学研究基金会 | 用于产生内胚层和中胚层细胞系及多能游走细胞(mmc)的早期中胚层细胞即稳定的中内胚层细胞群 |
EP2137296A2 (en) | 2007-03-23 | 2009-12-30 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
US20100111914A1 (en) | 2007-05-21 | 2010-05-06 | Yuanyuan Zhang | Stem cells from urine and methods for using the same |
FI20075417A0 (fi) | 2007-06-05 | 2007-06-05 | Marjo-Riitta Suuronen | Koostumuksia ja menetelmiä alkion kantasolujen kasvatukseen |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
KR101555824B1 (ko) | 2007-07-18 | 2015-09-25 | 라이프스캔, 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
WO2009052211A1 (en) | 2007-10-15 | 2009-04-23 | Caritas St. Elizabeth Medical Center Of Boston, Inc. | Compositions and methods for enhancing lymphangiogenesis |
US20110218143A1 (en) | 2007-11-20 | 2011-09-08 | University Of Florida Research Foundation | Compositions and methods for tissue repair |
AU2008338989A1 (en) * | 2007-12-17 | 2009-06-25 | Gliamed, Inc. | Stem-like cells and method for reprogramming adult mammalian somatic cells |
EP2254586B1 (en) | 2008-02-22 | 2015-04-08 | Agency For Science, Technology And Research (A*star) | Mesenchymal stem cell particles |
US20110038791A1 (en) * | 2008-02-25 | 2011-02-17 | Ford Heide L | Methods for inhibiting six1 and eya proteins |
WO2009120762A2 (en) | 2008-03-27 | 2009-10-01 | Mount Sinai School Of Medicine Of New York University | Human cardiovascular progenitor cells |
AU2009256202B2 (en) | 2008-06-04 | 2014-07-03 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of IPS cells using non-viral approach |
CA2695590C (en) | 2008-06-27 | 2018-01-09 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
WO2011150105A2 (en) | 2010-05-27 | 2011-12-01 | Biotime Inc. | Improved methods of screening embryonic progenitor cell lines |
US20130115673A1 (en) | 2008-07-16 | 2013-05-09 | Biotime, Inc. | Methods of Screening Embryonic Progenitor Cell Lines |
US20100184033A1 (en) | 2008-07-16 | 2010-07-22 | West Michael D | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby |
WO2010021993A1 (en) | 2008-08-19 | 2010-02-25 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease |
WO2010056337A2 (en) | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
WO2010062995A2 (en) * | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2 |
US8609927B2 (en) | 2009-05-28 | 2013-12-17 | Trustees Of Dartmouth College | Caveolin 1-reporter protein knock-in mouse |
ES2778750T3 (es) | 2009-07-16 | 2020-08-11 | Lineage Cell Therapeutics Inc | Métodos y composiciones para la condrogénesis in vitro e in vivo |
US20120148546A1 (en) | 2009-08-17 | 2012-06-14 | Technion Research & Development Foundation Ltd. | Pericyte progenitor cells and methods of generating and using same |
CN102858997B (zh) | 2009-11-02 | 2014-06-18 | 新加坡科技研究局 | 用于监测细胞状态和用于永生间充质干细胞的方法 |
US20110312881A1 (en) | 2009-12-21 | 2011-12-22 | Amunix, Inc. | Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases |
US20120301443A1 (en) | 2009-12-29 | 2012-11-29 | Cornell University | Methods for developing endothelial cells from pluripotent cells and endothelial cells derived |
US20130196865A1 (en) | 2010-03-03 | 2013-08-01 | The General Hospital Corporation | Method for selecting an ips cell |
WO2011127458A2 (en) | 2010-04-09 | 2011-10-13 | University Of Southern California | Systems and methods of cell activated, controlled release delivery of growth factors for tissue repair and regeneration |
EP2603592A2 (en) | 2010-08-13 | 2013-06-19 | The University Court of the University of Glasgow | Therapeutic uses of microvesicles and related micrornas |
SG10202109393RA (en) | 2010-09-07 | 2021-10-28 | Technion Res & Dev Foundation | Novel Methods And Culture Media For Culturing Pluripotent Stem Cells |
US20120093885A1 (en) | 2010-10-18 | 2012-04-19 | Northwestern University | Therapeutic vesicles |
WO2012065065A1 (en) | 2010-11-12 | 2012-05-18 | Follica, Inc. | Methods and compositions for modulating hair growth, wound healing and scar revision |
ES2629502T3 (es) | 2011-03-11 | 2017-08-10 | Children's Medical Center Corporation | Métodos y composiciones relacionados con exosomas de células madre mesenquimales |
PT3358011T (pt) * | 2011-04-26 | 2020-04-23 | Univ Osaka | Péptido para induzir a regeneração de um tecido e a sua utilização |
US20120295347A1 (en) | 2011-05-20 | 2012-11-22 | Steven Kessler | Methods and Compositions for Producing Endothelial Progenitor Cells from Pluripotent Stem Cells |
EP2726603B1 (en) | 2011-06-29 | 2020-04-01 | Biorestorative Therapies, Inc. | Brown fat cell compositions and methods |
ITRM20110403A1 (it) | 2011-07-28 | 2013-01-29 | Ospedale Pediatrico Bambino Gesu | Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori. |
US20140349396A1 (en) | 2011-09-09 | 2014-11-27 | Michael West | Compositions and Methods Relating to Clonal Progenitor Cells |
US9645149B2 (en) | 2011-09-30 | 2017-05-09 | The Regents Of The University Of Michigan | System for detecting rare cells |
TWI485253B (zh) | 2011-11-08 | 2015-05-21 | Univ Nat Cheng Kung | 用以偵測循環性癌幹細胞的方法與套組 |
KR101996343B1 (ko) | 2012-01-27 | 2019-07-05 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 전능성 줄기세포의 심근분화 유도방법 |
WO2013134022A1 (en) * | 2012-03-05 | 2013-09-12 | Wake Forest University Health Sciences | Regeneration of inner ear cells |
GB201302468D0 (en) | 2013-02-12 | 2013-03-27 | Reneuron Ltd | Stem cell product |
KR101993027B1 (ko) | 2012-04-03 | 2019-09-30 | 레뉴런 리미티드 | 줄기 세포 마이크로입자 |
WO2013172793A1 (en) | 2012-05-18 | 2013-11-21 | Agency For Science, Technology & Research | Umbilical cord mesenchymal stem cell exosomes |
US20140010801A1 (en) | 2012-06-08 | 2014-01-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Compositions and Methods for Restoring or Rejuvenating Stem/Progenitor Cell Function |
CA2879322A1 (en) | 2012-07-19 | 2014-01-23 | Reneuron Limited | Stem cell microparticles |
US20150216892A1 (en) | 2012-08-03 | 2015-08-06 | Aptamir Therapeutics, Inc. | Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders |
EP2882445B1 (en) | 2012-08-13 | 2019-04-24 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
US9175263B2 (en) | 2012-08-22 | 2015-11-03 | Biotime, Inc. | Methods and compositions for targeting progenitor cell lines |
AU2013237760A1 (en) | 2012-10-08 | 2014-04-24 | Biotime, Inc. | Differentiated progeny of clonal progenitor cell lines |
WO2014091373A1 (en) | 2012-12-11 | 2014-06-19 | The University Court Of The University Of Glasgow | Cellular and molecular therapies for peripheral vascular disease |
US20160002597A1 (en) | 2013-02-12 | 2016-01-07 | Reneuron Limited | Method of producing microparticles |
EP2991648A4 (en) | 2013-05-03 | 2017-01-18 | Microbiotix, Inc. | Antimicrobial potentiators |
US10961531B2 (en) | 2013-06-05 | 2021-03-30 | Agex Therapeutics, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
BR112016003053A2 (pt) | 2013-08-14 | 2017-09-12 | Reneuron Ltd | micropartículas de células tronco e mirna |
GB201317887D0 (en) | 2013-10-09 | 2013-11-20 | Reneuron Ltd | Product |
GB201317889D0 (en) | 2013-10-09 | 2013-11-20 | Reneuron Ltd | Product and use |
US20150275177A1 (en) | 2013-11-25 | 2015-10-01 | Biotime, Inc., | Methods For Generating Pluripotent Stem Cell-Derived Brown Fat Cells |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
US10265372B2 (en) * | 2014-08-12 | 2019-04-23 | The Regents Of The University Of California | Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues |
WO2017100313A1 (en) | 2015-12-07 | 2017-06-15 | Biotime, Inc. | Methods for the re-derivation of diverse pluripotent stem cell-derive brown fat cells |
AU2017278931B2 (en) | 2016-06-07 | 2023-06-29 | Agex Therapeutics, Inc. | Improved methods for detecting and modulating the embryonic-fetal transition in mammalian species |
US20190151372A1 (en) | 2017-06-19 | 2019-05-23 | Agex Therapeutics, Inc. | Pericyte cell exosomes |
CN112955141A (zh) | 2018-04-23 | 2021-06-11 | Agex治疗公司 | 用于在哺乳动物细胞中诱导组织再生和衰老细胞裂解的改善方法 |
-
2014
- 2014-06-03 US US14/896,664 patent/US10961531B2/en active Active
- 2014-06-03 CN CN201480044267.9A patent/CN105473134B/zh active Active
- 2014-06-03 AU AU2014275130A patent/AU2014275130B2/en active Active
- 2014-06-03 EP EP14807869.4A patent/EP3003290B1/en active Active
- 2014-06-03 EP EP21157975.0A patent/EP3888640A1/en active Pending
- 2014-06-03 CA CA2914615A patent/CA2914615C/en active Active
- 2014-06-03 CN CN202110388133.0A patent/CN113648323A/zh active Pending
- 2014-06-03 JP JP2016518393A patent/JP6529486B2/ja active Active
- 2014-06-03 WO PCT/US2014/040601 patent/WO2014197421A1/en active Application Filing
-
2019
- 2019-05-14 JP JP2019091651A patent/JP6821908B2/ja active Active
- 2019-12-09 AU AU2019279909A patent/AU2019279909B2/en active Active
-
2020
- 2020-12-17 JP JP2020209201A patent/JP2021054846A/ja active Pending
-
2021
- 2021-02-17 US US17/177,747 patent/US20220112492A1/en active Pending
- 2021-12-06 US US17/543,018 patent/US20220090078A1/en active Pending
-
2022
- 2022-01-13 AU AU2022200207A patent/AU2022200207A1/en active Pending
- 2022-05-02 JP JP2022075775A patent/JP2022105142A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US10961531B2 (en) | 2021-03-30 |
EP3888640A1 (en) | 2021-10-06 |
CN113648323A (zh) | 2021-11-16 |
EP3003290A1 (en) | 2016-04-13 |
JP2016523848A (ja) | 2016-08-12 |
CN105473134A (zh) | 2016-04-06 |
CN105473134B (zh) | 2021-04-27 |
AU2019279909A1 (en) | 2020-01-02 |
EP3003290A4 (en) | 2017-04-05 |
US20220112492A1 (en) | 2022-04-14 |
US20160186170A1 (en) | 2016-06-30 |
CA2914615A1 (en) | 2014-12-11 |
JP2022105142A (ja) | 2022-07-12 |
AU2022200207A1 (en) | 2022-02-10 |
AU2019279909B2 (en) | 2021-10-14 |
AU2014275130B2 (en) | 2019-09-12 |
JP2019163295A (ja) | 2019-09-26 |
AU2014275130A1 (en) | 2016-01-28 |
EP3003290B1 (en) | 2021-03-10 |
US20220090078A1 (en) | 2022-03-24 |
CA2914615C (en) | 2023-10-17 |
WO2014197421A1 (en) | 2014-12-11 |
JP2021054846A (ja) | 2021-04-08 |
JP6529486B2 (ja) | 2019-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6821908B2 (ja) | 哺乳動物種における誘導組織再生のための組成物および方法 | |
US20220160833A1 (en) | Methods for detecting and modulating the embryonic-fetal transition in mammalian species | |
JP7419347B2 (ja) | 哺乳動物細胞における組織再生の誘導及びセノリシスのための改良された方法 | |
US20240066070A1 (en) | Methods for the ex vivo induction of tissue regeneration in microbiopsies | |
WO2023064577A1 (en) | Methods for modulating the regenerative phenotype in mammalian cells | |
WO2023064572A2 (en) | Methods for the temporal regulation of reprogramming factors in mammalian cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190604 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20200407 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200703 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201006 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201020 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201113 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20201207 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201208 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6821908 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |